Ibarburu, S., Kovacs, M., Varela, V., Rodriguez-Duarte, J., Ingold, M., Inverizzi, P., Porcal, W., Arevalo, A.P., Perelmuter, K., Bollati-Fogolin, M., Escande, C., Lopez, G.V., King, P., Si, Y., Kwon, Y., Batthyany, C., Barbeito, L. and Trias, E. (2021) A Nitroalkene Benzoic Acid Derivative Targets Reactive Microglia and Prolongs Survival in an Inherited Model of ALS via NF-B Inhibition. Neurotherapeutics, 18, 309-325.
https://doi.org/10.1007/s13311-020-00953-z

has been cited by the following article:

• TITLE: Relative Molecular Similarity in Compound Structures Modulating Neurodegenerative Apoptosis

  AUTHORS: Wynford Robert Williams

  KEYWORDS: Apoptosis, cGMP, Neurodegeneration, Neurotoxins, Molecular Similarity

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.11 No.2, February 14, 2023

  ABSTRACT: Neurodegeneration is attributable to metabolic disturbances in the various cell types responsible for this condition, in respect of glucose utilisation and dysfunctional mitochondrial oxidative mechanisms. The properties of neurotoxins and antagonists that limit their action are well documented in disease models, whereas effective therapy is very limited. Cell apoptosis, a general marker of neurodegeneration, is also of therapeutic interest in the treatment of cancer. cGMP nucleotide influences apoptosis and has a role in maintaining equilibrium within cell redox parameters. The chemical structure of cGMP provides a comparative template for demonstrating relative molecular similarity within the structures of natural and synthetic compounds influencing tumour cell apoptosis. The present study uses computational software to investigate molecular similarity within the structures of cGMP and compounds that modulate cell apoptosis in experimental models of diabetic peripheral neuropathy (DPN), Parkinson’s and multiple sclerosis. Differential molecular similarity demonstrated in neurotoxin and antagonist structures implicate metabolite impairment of cGMP signaling function as a common mechanism in the initial phases of these neurodegenerative conditions.